Intellectual PropertyPositive updates from the patent dispute can support stock sentiment for Ceribell.
Market ExpansionCeribell's pipeline consists of initiatives designed to expand its Total Addressable Market, including recent label expansion into pediatrics and plans for extension into neonates and new indications like delirium and ischemic stroke.
Revenue GrowthCeribell's dual streams of recurring revenue from its single-use EEG headband and its subscription sales, reporting full-year gross margins of ~87% and $65.4M in total revenue, which represents 45% year-over-year growth.